Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
EVUSHELD Inj Lös 150 mg + 150 mg Amp
Drug
Evusheld, Injektionslösung
Behandlung und Prä-Expositionsprophylaxe von COVID-19
08.03.0. – antivirals
HAM – Human medicine
LSINJ – Solution for injection
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
9/9/2022
1/9/2029
Dosage strength
Evusheld, Injektionslösung
Behandlung und Prä-Expositionsprophylaxe von COVID-19
01
Z – approved
Package
7680687040013
No information made available
A/R – Authorised / referenced
1 x 2 vial(s)
001
Z – approved
Declaration
Component A)
150 mg tixagevimabum
histidinum
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
aqua ad iniectabile
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
aqua ad iniectabile
Component B)
150 mg cilgavimabum
histidinum
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
aqua ad iniectabile
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
aqua ad iniectabile
Authorisation holder
7601001348622
AstraZeneca AG
Neuhofstrasse 34
6340 Baar (ZG)
Neuhofstrasse 34
6340 Baar (ZG)
Date of revision of the text
2/1/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.